Takasu Keiko, Honda Motoko, Ono Hideki, Tanabe Mitsuo
Laboratory of CNS Pharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
Br J Pharmacol. 2006 May;148(2):233-44. doi: 10.1038/sj.bjp.0706731.
After partial nerve injury, the central analgesic effect of systemically administered gabapentin is mediated by both supraspinal and spinal actions. We further evaluate the mechanisms related to the supraspinally mediated analgesic actions of gabapentin involving the descending noradrenergic system. Intracerebroventricularly (i.c.v.) administered gabapentin (100 microg) decreased thermal and mechanical hypersensitivity in a murine chronic pain model that was prepared by partial ligation of the sciatic nerve. These effects were abolished by intrathecal (i.t.) injection of either yohimbine (3 microg) or idazoxan (3 microg), alpha(2)-adrenergic receptor antagonists. Pretreatment with atropine (0.3 mg kg(-1), i.p. or 0.1 microg, i.t.), a muscarinic receptor antagonist, completely suppressed the effect of i.c.v.-injected gabapentin on mechanical hypersensitivity, whereas its effect on thermal hypersensitivity remained unchanged. Similar effects were obtained with pirenzepine (0.1 microg, i.t.), a selective M(1)-muscarinic receptor antagonist, but not with methoctramine (0.1 and 0.3 microg, i.t.), a selective M(2)-muscarinic receptor antagonist. The cholinesterase inhibitor neostigmine (0.3 ng, i.t.) potentiated only the analgesic effect of i.c.v. gabapentin on mechanical hypersensitivity, confirming spinal acetylcholine release downstream of the supraspinal action of gabapentin. Moreover, the effect of i.c.v. gabapentin on mechanical but not thermal hypersensitivity was reduced by i.t. injection of L-NAME (3 microg) or L-NMMA (10 microg), both of which are nitric oxide (NO) synthase inhibitors. Systemically administered naloxone (10 mg kg(-1), i.p.), an opioid receptor antagonist, failed to suppress the analgesic actions of i.c.v. gabapentin, indicating that opioid receptors are not involved in activation of the descending noradrenergic system by gabapentin. Thus, the supraspinally mediated effect of gabapentin on mechanical hypersensitivity involves activation of spinal alpha(2)-adrenergic receptors followed by muscarinic receptors (most likely M(1)) and the NO cascade. In contrast, the effect of supraspinal gabapentin on thermal hypersensitivity is independent of the spinal cholinergic-NO system.
部分神经损伤后,全身给药的加巴喷丁的中枢镇痛作用由脊髓上和脊髓作用共同介导。我们进一步评估了与加巴喷丁脊髓上介导的镇痛作用相关的机制,该作用涉及下行去甲肾上腺素能系统。在通过坐骨神经部分结扎制备的小鼠慢性疼痛模型中,脑室内(i.c.v.)注射加巴喷丁(100微克)可降低热和机械超敏反应。鞘内(i.t.)注射育亨宾(3微克)或咪唑克生(3微克),即α₂-肾上腺素能受体拮抗剂,可消除这些作用。用毒蕈碱受体拮抗剂阿托品(0.3毫克/千克,腹腔注射或0.1微克,鞘内注射)预处理可完全抑制脑室内注射加巴喷丁对机械超敏反应的作用,而其对热超敏反应的作用保持不变。用选择性M₁-毒蕈碱受体拮抗剂哌仑西平(0.1微克,鞘内注射)也获得了类似的效果,但用选择性M₂-毒蕈碱受体拮抗剂甲溴东莨菪碱(0.1和0.3微克,鞘内注射)则没有。胆碱酯酶抑制剂新斯的明(0.3纳克,鞘内注射)仅增强了脑室内加巴喷丁对机械超敏反应的镇痛作用,证实了加巴喷丁脊髓上作用下游的脊髓乙酰胆碱释放。此外,鞘内注射L-NAME(3微克)或L-NMMA(10微克),二者均为一氧化氮(NO)合酶抑制剂,可降低脑室内加巴喷丁对机械超敏反应而非热超敏反应的作用。全身给药的阿片受体拮抗剂纳洛酮(10毫克/千克,腹腔注射)未能抑制脑室内加巴喷丁的镇痛作用,表明阿片受体不参与加巴喷丁对下行去甲肾上腺素能系统的激活。因此,加巴喷丁对机械超敏反应的脊髓上介导作用涉及脊髓α₂-肾上腺素能受体的激活,随后是毒蕈碱受体(最可能是M₁)和NO级联反应。相比之下,脊髓上加巴喷丁对热超敏反应的作用独立于脊髓胆碱能-NO系统。